SAN FRANCISCO, Sept. 15, 2016
SAN FRANCISCO, Sept. 15, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Stephen Sundlof, DVM, PhD, Chief Scientific Officer and Executive Vice President, Regulatory Affairs and Quality, will be serving on a panel at the BIO Animal Biotech Summit in Bethesda, Maryland on Thursday, September 22, 2016 at 3.30pm EDT. The panel discussion, titled "Barriers to Innovation: Regulation and Politics," will discuss the role of regulation in facilitating or impeding technological innovation. The conference is being held in the Grand Ballroom of the Bethesda Marriott.
About Kindred Biosciences, Inc.
Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/kindred-biosciences-to-participate-in-a-bio-animal-biotech-summit-panel-300329025.html
SOURCE Kindred Biosciences, Inc.PR Newswire
Last updated on: 15/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.